---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-23-000067"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:20:11.059487+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avanos clarifies Q2 2023 results beat consensus after third-party error

## Summary
- Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.
- Adjusted diluted EPS including discontinued ops was $0.37, ahead of consensus.
- Continuing operations: net sales $169.4M, diluted loss per share $0.09, adjusted EPS $0.24.
- RH business operating results reported as discontinued operations due to planned divestiture.

## SEC filing metadata
- accession: 0001606498-23-000067
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/0001606498-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/avns-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-23-000067
- JSON: https://secwatch.observer/filing/0001606498-23-000067.json
- Plain text: https://secwatch.observer/filing/0001606498-23-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.